Biotech Firm Immunic Closes Direct Stock Offering, Raises $5.1M
Immunic (IMUX) completes direct offering, raising $5.1 million. Aberdeen Investments leads the offering of 5,666,667 shares at $0.90 each. Titan Partners Group serves as the placement agent. The funding will support Immunic's clinical trials and operations.
This news matters as it showcases Immunic's successful fundraising efforts to support its pipeline of therapies for chronic inflammatory and autoimmune diseases. The company's progress in securing funding highlights its commitment to advancing treatments for these debilitating conditions.
